July 28, 2025 — Stereotaxis, a provider of surgical robotics for minimally invasive endovascular intervention, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its MAGiC Sweep catheter. MAGiC Sweep is a robotically navigated high-density electrophysiology (EP) mapping catheter, representing a significant advancement in the technology available to diagnose and treat complex arrhythmia patients.

July 25, 2025 — Data in recent staffing surveys from the American Society of Radiologic Technologists show that vacancy rates for all medical imaging disciplines are above the rates reported in 2020, according to the 2025 ASRT Radiologic Sciences Staffing and Workplace Survey. Vacancy rates represent the number of unfilled positions that are actively being recruited.

July 24, 2025 —  Royal Philips has announced a collaboration with Epic to integrate Philips’ suite of cardiac ambulatory monitoring and diagnostics services with Aura, the specialty diagnostics suite of the electronic health record (EHR) company.

This collaboration will offer the broadest cardiac care portfolio of any single service provider integrating with Aura to date. Philips will deliver a new level of interoperability between its ambulatory monitoring technologies and Epic — helping providers enhance the diagnostic process and improve patient outcomes. 

July 22, 2025 — In a collaboration between American Heart Association Ventures and the Association’s Center for Health Technology and Innovation, eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator.

July 21, 2025 — Long COVID patients with abnormal cardiopulmonary PET/MR findings may be more likely to develop heart and lung diseases, according to new research published in the July issue of The Journal of Nuclear Medicine. The study — which included the largest cohort of long COVID subjects with cardiopulmonary symptoms with the longest follow-up duration — suggests that abnormal cardiopulmonary PET/MR should be considered a risk factor for future cardiac and pulmonary disease and that closer monitoring is warranted in these patients.

July 16, 2025 — Medtronic has announced that the first patient has been enrolled in the PEripheral Onyx Liquid Embolic (PELE) clinical trial, which will evaluate the safety and effectiveness of the Onyx Liquid Embolic System (LES) for embolization of arterial hemorrhage in the peripheral vasculature. The first procedure was performed by Dr. Christopher Stark at Albany Medical Center.

July 22, 2025 — HeartBeam, Inc., a medical technology company focused on transforming cardiac care by providing powerful personalized insights, recently announced it has been awarded the Innovation Award in Remote Cardiac Diagnostics as part of the 2025 Medical Device Network Excellence Awards. The award honors HeartBeam’s  FDA-cleared electrocardiogram (ECG) technology that enables clinical-grade diagnostics for arrhythmia assessment outside of traditional healthcare settings, expanding access to timely and actionable cardiac care.

July 21, 2025. — Electrophysiologists at the Texas Cardiac Arrhythmia Institute (TCAI) at St. David's Medical Center recently became the first in the nation to implant an FDA-approved novel leadless system that provides cardiac resynchronization therapy to patients with heart failure. Cardiac resynchronization therapy improves the timing of the heart's contractions, helping to restore the normal rhythm of the heartbeat. The first procedure was recently performed by Robert Canby, M.D., cardiac electrophysiologist at TCAI.

July 17, 2025— Heartflow, Inc. recently announced new data for its AI-enabled Heartflow Plaque Analysis, including final primary endpoint data from the DECIDE Registry. Data from the DECIDE Registry showed Heartflow Plaque Analysis led to medical management change in over half of patients beyond coronary computed tomography angiography (CCTA) alone, regardless of traditional risk factors or CCTA findings.

July 17, 2025 — Royal Philips, a global leader in health technology, has launched the Philips ECG AI Marketplace, a platform that gives cardiac care teams access to multiple vendor offerings all in one central location to help clinicians manage and implement AI-powered diagnostic tools more easily. Anumana, an AI-driven health technology company committed to transforming the continuum of cardiac care, is the first organization to leverage Philips’ platform.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now